Pure Labels

Medical Marijuana Sciences, Inc. (MMS) is a subsidiary of Nuvilex that was established in early 2013. The initial mission of MMS is to develop treatments, based on constituents of Cannabis, for two of the most serious and deadly forms of cancer – brain and pancreatic cancers.

Based in Seattle, Plandai Biotechnology is a publicly-traded company that delivers highly bioavailable, phytonutrient rich extracts under the trademark, Phytofare™. In early 2014, Plandai submitted a request for ministerial dispensation to the Secretary of Parliament of South Africa, asking for the allowance of cannabis research. The company hopes to develop cannabis extract medicines for the treatment of cancer.

GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group’s lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.